Bottom line
Is XBI a good fund? The bottom line
XBI is an index technology sector ETF from SPDR (State Street).
Annual fees run 0.35% — about $35 a year on every $10,000 invested, cheaper than 90% of technology sector funds we track.
It returned +35.8% over one year, −2.7% a year over five years, +5.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $10.7 billion in net assets and 161 holdings, its largest position is State Street Global Advisors (5.9%) and the top 10 make up 18% of the portfolio.
What stands out
- Low cost: cheaper than 90% of technology sector peers
- Large and established ($10.7 billion)
What to watch
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What XBI invests in
The State Street SPDR S&P Biotech ETF (the Fund) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index.
In seeking to track the performance of the S&P Biotechnology Select Industry Index ? (the Index), the Fund employs a sampling strategy, which means that the Fund is not required to purchase all of the securities represented in the Index. Instead, the Fund may purchase a subset of the securities in the Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics of the Index. The quantity of holdings in the Fund will be based on a number of factors, including asset size of the Fund. Based on its analysis of these factors, SSGA Funds Management, Inc. (SSGA FM or the Adviser), the investment adviser to the Fund, either may invest the Fund's assets in a subset of securities in the Index or may invest the Fund's assets in substantially all of the securities represented in the Index in approximately the same proportions as the Index, as…
From the fund's prospectus (filed Oct 26, 2026).
XBI performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| XBI | +35.8% | −2.7% | +5.8% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What XBI costs
On a $10,000 investment, XBI's 0.35% expense ratio costs about $35 a year. The prospectus estimates $443 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
XBI top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | State Street Global Advisors | 5.87% |
| 2 | Apogee Therapeutics Inc | 1.49% |
| 3 | Moderna Inc | 1.41% |
| 4 | Twist Bioscience Corp | 1.41% |
| 5 | Oruka Therapeutics Inc | 1.38% |
| 6 | Kymera Therapeutics Inc | 1.36% |
| 7 | Viking Therapeutics Inc | 1.30% |
| 8 | Praxis Precision Medicines Inc | 1.29% |
| 9 | Erasca Inc | 1.27% |
| 10 | Revolution Medicines Inc | 1.20% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 18% of the fund. See all top 25 holdings and asset mix →